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ABSTRACT: The hormone oxytocin is commonly administered
during childbirth to initiate and strengthen uterine contractions
and prevent postpartum hemorrhage. However, patients have wide
variation in the oxytocin dose required for a clinical response. To
begin to uncover the mechanisms underlying this variability, we
screened the 11 most prevalent missense genetic variants in the
oxytocin receptor (OXTR) gene. We found that ﬁve variants,
V45L, P108A, L206V, V281M, and E339K, signiﬁcantly altered
oxytocin-induced Ca2+ signaling or β-arrestin recruitment and
proceeded to assess the eﬀects of these variants on OXTR traﬃcking to the cell membrane, desensitization, and internalization. The
variants P108A and L206V increased OXTR localization to the cell membrane, whereas V281M and E339K caused OXTR to be
retained inside the cell. We examined how the variants altered the balance between OXTR activation and desensitization, which is
critical for appropriate oxytocin dosing. The E339K variant impaired OXTR activation, internalization, and desensitization to
roughly equal extents. In contrast, V281M decreased OXTR activation but had no eﬀect on internalization and desensitization. V45L
and P108A did not alter OXTR activation but did impair β-arrestin recruitment, internalization, and desensitization. Molecular
dynamics simulations predicted that V45L and P108A prevent extension of the ﬁrst intracellular loop of OXTR, thus inhibiting βarrestin binding. Overall, our data suggest mechanisms by which OXTR genetic variants could alter clinical response to oxytocin.
KEYWORDS: oxytocin receptor, molecular dynamics, β-arrestin, pharmacogenetics, variants of unknown signiﬁcance, precision medicine
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release from intracellular stores, which promotes myometrial
smooth muscle contraction.10 OXTR signaling through Gq is
counteracted by coupling to β-arrestin, which mediates
desensitization and internalization of OXTR from the cell
surface.11−14 OXTR desensitization after oxytocin exposure
may impair myometrial contractions, leading to adverse events
including uterine atony and postpartum hemorrhage.6−8
Several investigators have tested the hypothesis that variants
in the OXTR gene aﬀect the response to exogenous oxytocin.
For example, Reinl et al. and Grotegut et al. identiﬁed single
nucleotide OXTR variants in patients who required high or low
doses of oxytocin to induce labor, but these studies were not
powered to detect signiﬁcant associations.15,16 In an ex vivo
study, one coding and one noncoding OXTR variant altered the
oxytocin-induced contractions of uterine tissue strips isolated

synthetic form of the hormone oxytocin is administered
to a large portion of pregnant patients in the United States
to induce or augment labor1 and to nearly all patients who
deliver to prevent postpartum hemorrhage.2 Oxytocin response
varies widely between individuals.3 For labor induction and
augmentation, maximal oxytocin infusion rates range from 2
milliunits/min (the starting rate speciﬁed in low-dose
protocols) to 40 milliunits/min (the maximal infusion rate
recommended by many providers).3 The duration of oxytocin
infusion required before delivery also varies by 50 h or more,
contributing to wide variations in the total oxytocin dose
received by patients.4 Patients who receive high oxytocin doses
are at increased risk for uterine hyperstimulation and rupture5
and postpartum hemorrhage secondary to uterine atony.6−8 In
contrast, patients who receive insuﬃcient oxytocin doses may
require Cesarean delivery, which puts them at risk for surgical
complications.9 To avoid these adverse events, clinicians have
sought to identify individual factors that predict oxytocin dose
requirement and thus enable personalized dosing of oxytocin.
The oxytocin receptor (OXTR) is a member of the G protein
coupled receptor (GPCR) family. To bind to oxytocin, OXTR
must ﬁrst traﬃc to the myometrial smooth muscle cell surface.
Upon oxytocin binding, OXTR activates Gq, leading to Ca2+
© 2021 The Authors. Published by
American Chemical Society
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from pregnant individuals.17 Although exome sequencing
studies have shown that missense variants in the OXTR gene
are prevalent in the global human population,18 the functional
eﬀects of most of these variants have not been determined.
However, prevalent missense variants in other GPCRs genes
lead to aberrant drug responses.19 Here, we assessed the eﬀects
of genetic variants of unknown signiﬁcance in OXTR on
oxytocin response in cells.

Article

oxytocin of the appropriate concentration and record the
ﬂuorescence intensity (excitation ﬁlter = 485/20 nm, emission
ﬁlter = 528/20 nm) every 0.14 s for 20 s/well. Fluorescence
increase (increase in intracellular Ca2+) was calculated as the
average of ﬂuorescence intensity readings from 10 to 20 s after
oxytocin addition minus the minimum ﬂuorescence intensity
averaged over ﬁve points from 0 to 10 s.
For desensitization assays, transfected cells were pretreated
with the indicated oxytocin concentrations for 30 min. Then,
without washing out the pretreatment oxytocin, a Synergy 2
plate reader was used to add a challenge dose of 1 μM oxytocin
and record response as above.
Bioluminescence Resonance Energy Transfer (BRET)
Assays. HEK293T cells (4 × 104) were plated in each well of
96-well white-walled, clear-bottom polystyrene microplates
coated with poly-D-lysine. The following day, cells were
transfected with WT or variant OXTR-GFP10 and β-arrestin1-Rluc8 or β-arrestin-2-Rluc8 at a ratio of 15:1 (w/w). For
transfections, 50 ng of DNA and 0.5 μL of Lipofectamine 2000
reagent (Thermo Fisher Scientiﬁc), both diluted in Opti-MEM
reduced-serum media, were added to each well. After 24 h,
media was removed and replaced with 100 μL of Hank’s
buﬀered salt solution (HBSS) supplemented with 20 mM
HEPES. A Synergy2 plate reader was used to add 100 μL of
assay buﬀer containing 10 μM coelenterazine 400a (Biotium,
Fremont, CA) and the indicated concentrations of oxytocin to
10 wells at a time. Luminescence at 520 and 400 nm was read
every 26 s for a total of 182 s. The BRET ratio was calculated as
the average ratios of emission at 520 nm/400 nm at the ﬁve
time points from 78 to 182 s. WT controls were tested on each
plate in parallel with variants.
Quantitative Flow Cytometry. HEK293T cells (1 × 106)
were plated in T25 ﬂasks and transfected the next day with HAOXTR-GFP, OXTR-GFP, or HA-OXTR. Cells were transfected with 300 ng of plasmid DNA and 4 uL of TransIT-LT1
reagent (Mirus Bio). Cells were detached 24 h later with
CellStripper (Corning) and collected by centrifugation. To
measure receptor internalization, cells were incubated with the
indicated concentration of oxytocin for 30 min before and
during detachment. Cells were incubated with an empirically
determined saturating concentration (8−16 μg/mL) of
phycoerythrin (PE)-conjugated anti-HA antibody (901518,
Biolegend, San Diego, CA) in staining buﬀer (0.5% BSA and
0.1% sodium azide in Ca2+/Mg2+-free PBS) on ice for 40 min
and then washed twice in staining buﬀer before ﬂow cytometry
to quantify cell surface OXTR. For quantiﬁcation of total
OXTR, the PE-labeled living cells were ﬁxed with 2%
paraformaldehyde and permeabilized with 0.5% Tween20 in
PBS. Cells were washed with 0.1% Tween 20 in PBS, incubated
with 16 μg/mL PE anti-HA antibody for 40 min at room
temperature, and washed twice before ﬂow cytometry.
Flow cytometry was performed on a CytoFLEX ﬂow
cytometer (Beckman Coulter, Indianapolis, IN). Three
technical replicates were performed for each experimental
condition, and data from 5000 transfected cells were collected
from each replicate. Three independent trials were performed.
SYTOX Blue (Thermo Fisher Scientiﬁc) was used to exclude
dead cells where appropriate. PE Quantibrite beads (BD
Biosciences) were used for calibration. Flow cytometry gating
was performed as follows: (1) forward and side scatter were
used to exclude debris; (2) forward scatter width vs height was
used to exclude doublets; (3) SYTOX blue staining was used to
identify dead cells; (4) GFP ﬂuorescence was used to gate

■

METHODS
Cell Culture. HEK293T cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium/Ham’s F12 medium
without phenol red and supplemented with 10% fetal bovine
serum and 25 μg/mL gentamicin. Cells were kept in a
humidiﬁed cell culture incubator at 37 °C with 5% CO2.
cDNA Constructs. The wild-type (WT) OXTR and P108A
OXTR constructs in pcDNA3.1(+) vector were a kind gift from
Dr. Jeﬀrey Murray (University of Iowa). Other missense single
nucleotide variants were introduced by site-directed mutagenesis (Genewiz, South Plainﬁeld, NJ). The WT OXTR
sequence was identical to the coding region of the National
Center for Biotechnology Information reference sequence
NM_000916.3.
The β-arrestin-1-Rluc8 fusion construct in the vector
pcDNA3.1(+) encoded β-arrestin-1 with a C-terminal linker
SGGSTSA followed by Rluc8. The β-arrestin-2-Rluc8 fusion
construct in the vector pcDNA3.1(+) encoded β-arrestin-2
with a C-terminal linker GGGSEF followed by Rluc8. The
template cDNA clones for β-arrestin-1 (ARRB100002) and βarrestin-2 (ARRB200001) were obtained from the cDNA
Resource Center (Bloomsberg, PA, www.cdna.org). A plasmid
containing the Rluc8 cDNA was a kind gift from Dr. Brian
Finck (Washington University in St. Louis).
The OXTR-GFP10 fusion construct in the vector pcDNA
3.1(+) encoded OXTR with a C-terminal linker SGGKL
followed by GFP10. A plasmid containing the GFP10 cDNA
was a kind gift Dr. Céline Gales (INSERM, France).
The plasmid encoding OXTR-GFP was a gift from Christian
Gruber (Addgene plasmid #67848; http://n2t.net/
addgene:67848; RRID: Addgene_67848).20 Note that this
plasmid includes the missense single nucleotide variant A218T,
which was corrected before introducing the variants of interest.
An N-terminal HA tag was added (linker GPT) to generate the
HA-OXTR-GFP construct.
All plasmids were conﬁrmed by bidirectional Sanger
sequencing.
Oxytocin (Tocris Bioscience, Minneapolis, MN) stock
solutions diluted to 500 μM in water were stored at −80 °C
until just before use.
Ca2+ Assays. HEK293T cells (2 × 104) were plated in each
well of 96-well black-walled, clear-bottom polystyrene microplates coated with poly-D-lysine. The following day, cells were
transfected with a construct encoding WT or variant OXTR.
Each variant was tested alongside WT controls on the same
plate. For transfections, 50 ng of DNA and 0.5 μL of TransIT293 reagent (Mirus Bio, Madison, WI) diluted in Opti-MEM
reduced-serum media (Thermo Fisher Scientiﬁc, Waltham,
MA) were added to each well. After 24 h, media was removed
and replaced with 100 μL of Brilliant Calcium indicator
solution (Ion Biosciences, San Marcos, TX), which was
prepared by diluting Brilliant Calcium indicator, DrySolv, and
TRS reagent in assay buﬀer. After incubation for 1 h, a Synergy2
plate reader (BioTek, Winooski, VT) was used to add 100 μL of
1544
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interactions to zero between 1.0 and 1.2 nm. The Verlet cutoﬀ
scheme was used for the neighbor list. The Nosé−Hoover
thermostat was used to hold the temperature at 300 K.34 The
semi-isotropic Parrinello−Rahman barostat was used to
maintain constant pressure of 1 bar as is standard in protein−
membrane simulations.35 Conformations were stored every 20
ps.
The FAST algorithm36,37 was used to enhance conformational sampling for each OXTR sequence (WT, P108A,
V281M, and V45L). Five FAST simulation rounds were
conducted with 10 simulations per round. Each simulation
was 50 ns in length (2.5 μs aggregate simulation). To explore
away from the starting structure, the FAST ranking function
favored restarting simulations from states that had the fewest
number of preserved native contacts. Additionally, a similarity
penalty was added to the ranking to promote conformational
diversity in starting structures, as described previously.38
DiﬀNet Analysis. DiﬀNets can perform dimensionality
reduction in a way that highlights biochemically relevant
diﬀerences between data sets.39 Two DiﬀNets were independently trained to learn about impairment of β-arrestin and Gq
signaling. All DiﬀNet training and analysis was conducted under
the assumption that the regions of Gq and β-arrestin binding
were most likely to contain diﬀerences that explained impaired
Gq or β-arrestin signaling. Therefore, the DiﬀNet analysis only
considered atoms in the binding region (as shown in Figure
S1). All simulation data (2.5 μs per variant) was converted to
DiﬀNet input as described previously.39 Brieﬂy, XYZ atom
coordinates from simulations were mean-shifted to zero and
then multiplied by the inverse of the square root of a covariance
matrix, which was calculated from simulations. To learn about
β-arrestin impairment, a DiﬀNet was trained to classify all
structures from V45L and P108A as β-arrestin impaired (i.e.,
initial labels of one) and WT and V281M simulations as normal
(i.e., initial labels of zero). To learn about Gq impairment, a
DiﬀNet was trained to classify structures from V281M
simulations as potentially Gq impaired and WT, V45L, and
P108A simulations as normal. In both cases, the labels were
iteratively updated in a self-supervised manner described
previously39 in which expectation maximization bounds of
[0.1−0.4] were chosen for normal variants and [0.6−0.9] for
impaired variants. Both training sessions used 10 latent
variables, 10 training epochs in which the data were subsampled
by a factor of 10 in each epoch, a batch size of 32, and a learning
rate of 0.0001.
Markov State Model Construction and Analysis. A
Markov State Model (MSM) is a statistical framework for
analyzing molecular dynamics simulations and provides a
network representation of a free energy landscape.40−42 To
quantify diﬀerences between variants, several measurements
were made that relied on MSMs, each built with 2.5 μs of
simulation data for each variant. All MSMs were constructed
with Enspara,43 a python library for clustering and building
MSMs from molecular simulation data. In this work, Enspara
was used to cluster OXTR structures, count transitions between
clusters, and derive equilibrium probabilities of structural states
explored during simulation. A separate MSM was built for each
variant, using the same methodology for each variant. Namely,
simulation frames were converted from XYZ atom coordinates
to a vector containing a value indicating the amount of solventaccessible surface area (SASA) of each residue side chain (i.e.,
the data was SASA featurized). SASA calculations were
computed by using the Shrake−Rupley algorithm44 (with a

transfected cells (GFP+ population). The GFP+ threshold was
determined relative to the GFP signal in the GFP-negative
control (cells transfected with HA-OXTR).
The number of receptors on transfected cells was calculated
from the geometric mean of PE ﬂuorescence intensity
calibrated to PE standards as previously described.21 Values
from nonspeciﬁc binding of PE-HA antibody to HA-negative
cells (cells transfected with OXTR-GFP) were subtracted from
all samples.
Data Processing for Ca2+, BRET, Desensitization, and
Internalization Assays. For Ca2+ and BRET assays, responses
were normalized by subtracting the average basal response from
all samples and then dividing by the average WT response at the
highest oxytocin concentration for each trial. For desensitization and internalization experiments, responses were normalized by dividing values from all samples by the average response
from the corresponding nonpretreated sample(s). Normalization was performed separately for each replicate experiment.
Nonlinear regression with least-squares ﬁtting was used to
generate dose−response curves and calculate Emax, EC50, and
IC50 values (GraphPad Prism 8). The three-parameter
regression method, which was used to ﬁt the BRET data and
internalization data, used the model: Y = Bottom + (Top −
Bottom)/(1 + 10(log(EC50) or IC50−X)). The four-parameter regression method, which was used to ﬁt the Ca2+ activation and
desensitization data, used the equation Y = Bottom + (Top −
Bottom)/(1 + 10((log(EC50) or IC50−X)×HillSlope)). In these models, Y
= response, X = log(oxytocin concentration), and no
constraints were placed on any values. Buﬀer controls were
assigned a nominal concentration value of 10−9 M for BRET
assays or 10−12 M for all other assays.
All experiments were performed in triplicate, with WT
controls tested alongside each variant on the same plate to
control for day-to-day variation in assay response. Average
values from three biological replicates were used to construct
dose−response curves for each variant and the matched WT
controls, which were compared by performing nested extra
sum-of-squares F tests. F statistics were calculated and P-values
were determined as previously described.22,23 P-values shown
reﬂect comparisons of log EC50 values or Top values (see
equations above), as indicated.
Molecular Dynamics Simulations. The initial homology
model of WT OXTR was provided by the I-TASSER GPCR
homology model database.24 This model was then prepared for
simulation by the CHARMM-GUI membrane protein input
generator.25−28 Mutations (e.g., V281M) and palmitate lipid
tails on C346 and C347 were introduced by the CHARMMGUI PDB manipulator.29 All proteins were simulated in 0.15 M
KCl (111 K+ ions and 92 Cl− ions) in a rectangular box of size
99.5 × 99.5 × 171.2 Å with a membrane consisting of 121
(upper leaﬂet) or 120 (lower leaﬂet) POPC molecules and 12
cholesterol molecules (upper and lower leaﬂet). All systems
contained ∼100 000 TIP3P30 water molecules. Systems were
minimized in the default manner supplied by CHARMM-GUI.
Brieﬂy, using the CHARMM36m force ﬁeld,31 each system’s
energy was minimized by using gradient descent, then
simulated NVT with progressively weaker and fewer restraints
on positions of atoms and membrane components.
Production runs were performed in GROMACS.32 Hydrogen bonds were constrained with the LINCS algorithm.33
Cutoﬀs of 1.2 nm were used for the neighbor list, Coulomb
interactions, and van der Waals interactions. The force-switch
modiﬁer was used to smoothly switch forces from van der Waals
1545
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solvent probe radius of 0.28 nm) as implemented in the python
package MDTraj.45 SASA featurization was used for subsequent
clustering because, unlike other clustering schemes (e.g.,
RMSD-based), SASA emphasizes the conformational changes
of surface residues over internal residues, which should be most
useful for understanding signaling of a transmembrane receptor
that has a surface for binding ligands. Next, the SASA-featurized
data were clustered with a hybrid clustering algorithm. First, a
k-centers algorithm46 was used to cluster the data into 1000
clusters. Next, three sweeps of k-medoids update steps were
applied to reﬁne the cluster centers to be in the densest regions
of conformational space. Then, transition probability matrices
were produced by counting transitions between states (i.e.,
clusters) using a 2 ns lag time, adding a prior count of 1 and
Nstates

row-normalizing, as described previously.47 Equilibrium populations were calculated as the eigenvector of the transition
probability matrix with an eigenvalue of one. For the distance
histograms in Figures 6 and 7, the distance for each cluster
center (i.e., representative structure of the cluster) was
calculated and the distance was weighted by the corresponding
equilibrium population calculated with the MSM. Similar
calculations performed with an MSM built on an RMSD-based
clustering scheme produced similar results (Figure S2).

■

RESULTS
Genetic Variation Occurs in Several Locations within
OXTR. We searched the worldwide gnomAD v2.1 data set,18
which includes 141,456 exomes, to identify the most prevalent
single nucleotide missense variants in OXTR. We identiﬁed 11
OXTR variants (Table 1) with allele counts greater than 50,
Table 1. OXTR Variants for Studya
variant
5.56

A218T
A238T
V172A4.61
L206V5.44
E339K
G221S5.59
G252A
V281M6.41
V45L1.38
R376G
P108A

location

allele count in gnomAD

aﬀected (%)

TM5
ICL3
TM4
TM5
C-terminus
ICL3
ICL3
TM6
TM1
C-terminus
ECL1

41 562
5067
1613
551
308
215
178
107
91
89
74

27.09
3.87
1.14
0.39
0.22
0.15
0.14
0.08
0.09
0.06
0.05

a

Aﬀected (%): Percent of gnomAD participants with sequencing
coverage at that locus who were homozygous or heterozygous for that
variant. ECL: extracellular loop. ICL: intracellular loop. TM:
transmembrane domain. Ballesteros−Weinstein numbering48 is
shown for TM residues (superscripts).
Figure 1. Screen identiﬁes OXTR variants that alter oxytocin response
in Ca2+assays and β-arrestin recruitment assays. (A) Variant residues
within OXTR. ICL: intracellular loop. ECL: extracellular loop. (A−G)
Plots show EC50 (B, D, F) and Emax (C, E, G) for dose−response
curves for each variant, relative to WT value (100%). Variants shown
in red were chosen for further study on the basis of large eﬀect size and
statistical signiﬁcance (see Tables S1−S3). Error bars show standard
error of the mean from N = 3 independent experiments with three to
ﬁve technical replicates per experiment.

indicating that they were detected in more than 50
heterozygous individuals.18 These variants aﬀected residues in
multiple domains, including six residues in transmembrane
domains (TMs), one in the ﬁrst extracellular loop (ECL1), two
in the third intracellular loop (ICL3), and two in the C-terminal
tail (Table 1, Figure 1A). The gnomAD cohort includes
homozygotes for the four most common variants: A218T,
A238T, V172A, and L206V. The most prevalent variant,
A218T, was found in 27% of gnomAD participants; the 11th
most prevalent variant, P108A, was found in 0.05% of
participants.

OXTR Missense Variants Alter Ca2+ Signaling and βArrestin Recruitment. We reasoned that the missense
1546
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variants most likely to aﬀect clinical oxytocin response would
alter oxytocin-induced Ca2+ signaling, which is required for
myometrial smooth muscle contraction, or recruitment of βarrestin, which is thought to mediate OXTR desensitization.13
Therefore, to prioritize variants for further study, we transiently
transfected plasmids encoding wild-type (WT) OXTR or the
11 variants into HEK293T cells and then performed highthroughput assays to measure eﬀects on these pathways. First,
to measure increases in intracellular Ca2+ in response to
oxytocin, we used a ﬂuorescent Ca2+ indicator dye. Second, to
measure β-arrestin recruitment in response to oxytocin, we
performed bioluminescence resonance energy transfer assays in
HEK293T cells transfected with green ﬂuorescent protein
(GFP)-tagged OXTR and luciferase-tagged β-arrestin-1 or βarrestin-2. V45L, P108A, L206V, V281M, and E339K had the
largest statistically signiﬁcant eﬀects on EC50 or Emax in two or
more assays and were therefore selected for further study
(Figure 1, Tables S1−S3). V45L decreased the Emax for βarrestin-1 recruitment and increased the EC50 for β-arrestin-2
recruitment (Figure S3). P108A increased the EC50 for βarrestin-1 recruitment and increased both the EC50 and the Emax
for β-arrestin-2 recruitment. L206V increased the Emax for βarrestin-1 and β-arrestin-2 recruitment. V281M increased the
EC50 for Ca2+ signaling and decreased the Emax for Ca2+
signaling and β-arrestin-2 recruitment. Finally, E339K increased
the EC50 for Ca2+ signaling and decreased the Emax for Ca2+
signaling, β-arrestin-1 recruitment, and β-arrestin-2 recruitment
(Figure 1).
OXTR Variants Alter Cell Surface Localization. To
quantify the eﬀect of these ﬁve genetic variants on OXTR
quantity and localization to the plasma membrane, we
performed quantitative ﬂow cytometry. A speciﬁc OXTR
antibody is not commercially available, so we created a plasmid
encoding the OXTR fusion protein HA-OXTR-GFP. We used
GFP ﬂuorescence to diﬀerentiate transfected from untransfected cells, and a phycoerythrin (PE) -conjugated anti-HA
antibody to quantify the HA epitope on the extracellular Nterminus of OXTR. To quantify surface OXTRs, living cells
were labeled by PE; to quantify total OXTRs throughout the
cell, an additional PE-labeling step was performed after ﬁxing
and permeabilizing the PE-labeled living cells.
No variants had a statistically signiﬁcant eﬀect on the total
number of OXTRs per cell after adjusting for multiple
comparisons (P > 0.01 in one-sample t tests, Figure 2A).
However, two variants (P108A and L206V) increased the
number of cell surface OXTRs by 23 ± 3% and 41 ± 4%,
respectively (P = 0.0003 and P = 0.0002, one sample t tests).
Conversely, two variants (V281M and E339K) decreased the
number of cell surface OXTRs by 49 ± 0.7% and 36 ± 2%,
respectively (P < 0.0001, one-sample t tests, Figure 2B).
When we graphed cell surface OXTRs as a percentage of total
OXTRs (Figure 2C), we found that 21 ± 2% of total WT
OXTRs were localized to the plasma membrane. P108A and
L206V increased OXTR surface localization to 25 ± 1% and 27
± 1%, respectively (adjusted P = 0.03 for both). Conversely,
V281M and E339K decreased OXTR surface localization to 12
± 1% and 17 ± 1%, respectively (adjusted P = 0.01 for both).
V45L, P108A, and E339K Impair OXTR Desensitization
and Internalization. OXTR internalization and desensitization, mediated in part by β-arrestin recruitment, are thought to
be responsible for some adverse eﬀects associated with oxytocin
exposure, including uterine atony and postpartum hemorrhage.13 Thus, to assess the potential clinical implication of
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Figure 2. Genetic variants alter quantity of OXTR on the cell
membrane. (A) Total number of OXTRs, (B) the number of OXTRs
on the cell surface, and (C) the percentage of OXTRs on the cell
surface in HEK293T cells transfected with plasmids encoding wild
type (WT) and variant HA-OXTR-GFP. For (A) and (B), values for
variants are shown as percent diﬀerence from the WT OXTR value.
Error bars show standard error from N = 3−6 independent
experiments with 15 000 cells across 3 technical replicates per
experiment. Asterisk (*) indicates variant value diﬀers from 0 with P
< 0.01 in one-sample t test (B) or diﬀers from WT with P < 0.05 in
one-way repeated measures ANOVA with posthoc Dunnet multiple
comparisons test (omnibus P = 0.0024) (C).

variants, we aimed to deﬁne their eﬀects on OXTR
desensitization and internalization. As expected, for all ﬁve
variants, relative diﬀerences in the number of cell surface
receptors (Figure 2) corresponded to the diﬀerences seen in
maximal β-arrestin recruitment assays (Figure 1E, G). For
example, P108A and L206V had elevated Emax values for βarrestin-2 recruitment and elevated membrane localization,
whereas V281M and E339K had decreased Emax values for βarrestin recruitment decreased membrane localization. In
contrast, diﬀerences in the EC50 of β-arrestin recruitment did
not correspond to changes in cell surface receptor number. For
example, V45L increased the EC50 of β-arrestin-2 recruitment
but had no eﬀect on membrane localization, and P108A
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Figure 3. Method and data processing for desensitization and internalization assays. For desensitization assays, cells were incubated with indicated
oxytocin doses for 30 min and then challenged with 1 μM oxytocin. The Ca2+ increase in response to 1 μM challenge is shown. For internalization
assays, cells were incubated with indicated oxytocin doses for 30 min and then analyzed by quantitative ﬂow cytometry to measure surface OXTR.

increased the EC50 of both β-arrestin-1 and β-arrestin-2
recruitment and increased membrane localization. We
hypothesized that increased EC50 values would reﬂect functional deﬁcits in OXTR desensitization and internalization.
To measure desensitization, we pretreated cells expressing
WT OXTR or the ﬁve variants with varying concentrations of
oxytocin for 30 min and then used Ca2+ indicator assays to
measure the cellular response to a saturating concentration (1
μM) of oxytocin (Figure 3). To measure internalization, we
incubated cells with varying concentrations of oxytocin for 30
min and then performed quantitative ﬂow cytometry to
measure surface OXTRs (Figure 3). We found that V281M
and L206V had no eﬀect on either receptor desensitization or
internalization (P > 0.05, extra sum-of-squares F test). In
contrast, V45L, P108A, and E339K caused a rightward shift in
the dose−response curve and increased the IC 50 for
desensitization (P = 0.0001, P < 0.0001, and P < 0.0001,
extra sum-of-squares F test, Figure 4B, Table S4). V45L and
P108A caused a similar rightward shift in internalization assays
(P = 0.0098 and P = 0.0003, extra sum-of-squares F test, Figure
4C, Table S4). Although E339K did not cause a statistically
signiﬁcant increase in EC50 for internalization (P > 0.05), it
prevented maximal internalization, with 44% of E339K OXTRs
versus 24% of WT OXTRs remaining on the cell surface (P =
0.0001, Figure 4C).
Three of the ﬁve variants investigated had diﬀerential eﬀects
on OXTR activation (oxytocin-induced Ca2+ signaling in Figure
4A), desensitization (Figure 4B), and internalization (Figure
4C). These variants altered the balance between OXTR
desensitization and activation at any given dose of oxytocin
(Figures 4D and S4). Of the three variants that impaired OXTR
internalization and desensitization, only one, E339K, also
altered potency and eﬃcacy for OXTR activation, potentially
due to decreased cell surface localization (Figure 2B). V281M
had similar eﬀects as E339K on OXTR cell surface localization
and OXTR activation but had no eﬀect on OXTR internalization or desensitization (Figure 4). In contrast, V45L and

P108A impaired OXTR internalization and desensitization
without altering OXTR activation (Figure 4).
Variants that Reduce Desensitization and Internalization Alter OXTR Structural Conformations. In our in
vitro assays, two variants (V45L and P108A) reduced β-arrestin
recruitment, OXTR internalization, and OXTR desensitization
compared to WT OXTR. Thus, three lines of evidence suggest
that V45L and P108A decrease OXTR’s ability to activate βarrestin. To deﬁne the structural basis of β-arrestin impairment,
we used molecular dynamics simulations to computationally
model the motions of all atoms in WT and variant OXTRs in
solution over time (Figure 5A, B). We paired these simulations
with the FAST algorithm (see Methods36,37) to enhance
sampling of the conformational ensemble (i.e., the set of
structural poses the receptor adopts) of each variant.
To identify the conformational changes most associated with
β-arrestin impairment, we used DiﬀNets, deep-learning
algorithms that are trained to identify biochemically relevant
diﬀerences between multiple conformational ensembles (see
Methods).39 We ﬁrst trained a DiﬀNet to identify diﬀerences
between conformational ensembles of the two β-arrestinimpaired OXTRs (V45L and P108A) and two OXTRs (WT
and V281M) with normal desensitization and internalization.
From this training, the DiﬀNet learned a label for each
simulation frame (structural conﬁguration) from zero to one
that indicated the probability that it was associated with this
classiﬁcation. To interpret these labels, we calculated the
correlation between interatom distances in the OXTR cytosolic
region (71 289 possible distances, Figure S1) and changes in
the DiﬀNet label. We then plotted the 100 distances that were
most correlated with the DiﬀNet label (Figure 5C). This
analysis showed clear enrichment in distances that cluster at the
interface between transmembrane domain 1 (TM1) and the
ﬁrst intracellular loop (ICL1), indicating that changes in this
region were associated with β-arrestin impairment.
Conformational Changes in V45L and P108A OXTRs
Disrupt Putative β-Arrestin Binding Sites. DiﬀNets
identiﬁed locations associated with reduced β-arrestin function
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Figure 4. OXTR variants alter receptor activation, desensitization, and internalization. (A) Activation: increase in intracellular Ca2+ concentration in
HEK293T cells transfected with wild type (WT) or variant OXTR and treated with oxytocin. Results are normalized to WT value at highest oxytocin
concentration. (B) Desensitization: increase in intracellular Ca2+ concentration in cells treated with 1 μM oxytocin after pretreatment (PT) with the
indicated oxytocin concentration. Results are normalized to response without PT. (C) Internalization of OXTR from the cell surface after PT with
indicated oxytocin concentration. (D) Bias plot showing relative activation (y values from regression in (A)) and relative desensitization (regression
of 1 − y from (B)). See also Figure S4. P-values for diﬀerence in log(EC50) or log(IC50) between WT and variant are shown (extra sum-of-squares F
test, see also Tables S1 and S4). Error bars show standard error of the mean from N = 3 independent experiments.

predicted to have a shorter ICL1 than OXTRs with normal βarrestin function.
This conformational change has important implications for
β-arrestin binding. First, shortening ICL1 may prevent the
interactions between ICL1 and the bottom loop of β-arrestin
(Figure 6B) previously described by Yin et al.49 Second,
shortening ICL1 reduces the distance between ICL1 and helix 8
(H8), causing a collapsed state (Figure 6C). When we
superimposed bound structures of β-arrestin and G protein
(from other GPCRs49,50) onto the OXTR homology model, the
model predicted that this shortened distance created a steric
clash between ICL1 and the β-arrestin ﬁnger loop, but not
between ICL1 and the G protein (Figure 6D). Taken together,
our data suggest that the mechanism underlying reduced βarrestin function was similar in V45L and P108A OXTR.

without any prior information about functional sites in OXTR.
To determine whether the DiﬀfNet predictions corresponded
to functional locations, we used the simulation data to build
Markov State Models. Markov State Models provide a discrete
map of structural conﬁgurations and an equilibrium population
value that corresponds to the proportion of time a protein
spends in a given conﬁguration.40−42 The DiﬀNet prediction
implicated the TM1-ICL1 region in β-arrestin impairment, so
we used Markov State Models to more closely examine this
region. In this analysis, V45L and P108A introduced an
additional helical turn at the C-terminus of TM1 that was not
present in WT and V281M OXTR. Speciﬁcally, we found that
the hydrogen bond between Val60 and Leu64 was shorter in
V45L and P108A OXTR than in WT and V281M OXTR (0.2
vs 0.6 nm) (Figure 6A). Thus, β-arrestin-impaired OXTRs were
1549
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Figure 5. DiﬀNets identify distances associated with V45L, P108A, and V281M OXTR. (A, B) Homology model for OXTR showing the location of
V45L, P108A, and V281M. Structures for β-arrestin-1 (red, PDB: 6pwc49) and Gαs (blue, PDB: 3sn650) are superimposed on the OXTR structure.
(C) Dotted lines show the 100 interatom distance changes most associated with DiﬀNet label (V45L and P108A vs WT and V281M). (D) Distance
changes most associated with DiﬀNet label (V281M vs WT, V45L, P108A). TM: transmembrane domain. ICL1: intracellular loop 1. H8: helix 8.

Structural Conformations in V281M OXTR. Our results
in Figure 4D indicated that the balance between OXTR
activation and desensitization in V281M OXTR deviated
signiﬁcantly from WT, with greater relative desensitization for
any given unit of activation. We observed the opposite
deviation in V45L and P108A OXTR, both of which had less
relative desensitization for any given unit of activation. To
investigate the structural basis of this diﬀerence, we used a
similar approach as above and trained a second DiﬀNet to
identify diﬀerences between conformational ensembles of
V281M OXTR and V45L, P108A, and WT OXTR. We plotted
the 100 distances that were most correlated with the DiﬀNet
label in Figure 5D. This analysis showed enrichment for
distances between transmembrane domains 3 and 5 (TM3 and
TM5), indicating that structural rearrangements in this region
were associated with V281M.
We then used Markov State Models to plot the probability
that OXTR adopts a conformation with a given distance
between TM3 and TM5. V281M OXTR was more likely to
adopt conformations with a shorter distance between TM3 and
TM5 than were WT, V45L, and P108A OXTR (0.8 nm versus
1.2−1.4 nm, Figure 7A). When we superimposed the bound β-

arrestin and G protein structures, we saw that this collapsed
state caused a steric clash with the G protein but not with βarrestin (Figure 7B). This ﬁnding suggests that V281M
disrupted the binding of Gq to OXTR without aﬀecting βarrestin recruitment.

■

DISCUSSION
Our data indicate that OXTR variants found in the global
human population signiﬁcantly altered OXTR function.
Speciﬁcally, these variants altered oxytocin response by
changing OXTR localization to the cell membrane, decreasing
oxytocin-induced Ca2+ signaling, altering β-arrestin recruitment
and signaling, or a combination of these eﬀects. The variants
P108A and L206V increased the percentage of OXTR on the
cell membrane, whereas V281M and E339K caused OXTR to
be retained inside the cell. V281M and E339K also decreased
Ca2+ signaling. Three variants (V45L, P108A, and E339K)
impaired OXTR desensitization and OXTR internalization
upon exposure to oxytocin. Our molecular dynamics simulations predict that both V45L and P108A introduce an extra
helical turn at the end of TM1, which may explain the impaired
coupling to β-arrestin seen in vitro.
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Figure 6. Potential mechanism for altered β-arrestin function in V45L and P108A OXTR. (A) Distribution of the probability-weighted density for
the hydrogen bond distance between the most C-terminal TM1 helix i, i + 4 residue pair (Val60 and Leu64). β-Arrestin-impaired variants (V45L and
P108A) have a high probability of having a tight helix, whereas OXTRs with normal desensitization and internalization (WT and V281M) are more
likely to lack this hydrogen bond. (B) Representative structures from each peak in (A). The β-arrestin-1 “bottom loop” (red), which is involved in
binding to ICL1, is closer to ICL1 when ICL1 is extended. (C) Distribution of the probability-weighted density for ICL1-H8 distances that each
OXTR variant occupies. V45L and P108A have strong, left-shifted peaks indicating a collapse between ICL1 and H8. (D) Representative structures
of ICL1-H8 at collapsed distances (brown) and open distances (yellow). In the collapsed position, there is a steric clash between ICL1 and β-arrestin.
TM: transmembrane domain. ICL1: intracellular loop 1. H8: helix 8.

Figure 7. Conformational changes in V281M OXTR may reduce G protein binding. (A) Histogram showing a probability-weighted distribution of
TM3-TM5 distances that each OXTR variant occupies. V281M OXTR is highly likely to adopt a collapsed state that would sterically hinder G
protein binding. (B) Representative structures of TM3 and TM5 at collapsed distances (brown) and open distances (yellow). The collapsed position
sterically clashes with the G protein (blue) but not β-arrestin (red). TM: transmembrane domain.

Our results from the V281M and E339K variants highlight
the importance of eﬃcient membrane traﬃcking for receptor
function. These intracellularly retained variants were the only
two variants studied that decreased oxytocin-induced Ca2+

signaling (Figure 1B, C). In contrast, P108A and L206V,
which increased the number of OXTR on the cell surface, did
not increase maximal Ca2+ signaling. This may be because Ca2+
signaling becomes saturated at a certain concentration of
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were also likely due, at least in part, to ineﬃcient cell membrane
localization of V281M OXTR (Figure 2). Therefore, further in
vitro studies are necessary to determine whether V281M OXTR
displays decreased binding to Gq and thus validate the
predictions from our molecular dynamics simulations.
Our ﬁndings add to two previous in vitro studies examining
human OXTR variants. First, Ma et al. showed that R376G, a
variant associated with autism spectrum disorder, increased the
rate of OXTR internalization and recycling to the cell surface
after treatment with oxytocin.53 It is unclear whether the small
changes in β-arrestin recruitment seen in our screening assays
(Tables S2 and S3) explain the diﬀerences in OXTR
internalization and recycling observed by Ma et al. Second,
Kim et al. characterized three missense OXTR variants,
including P108A, that they identiﬁed in patients who
experienced premature labor.54 These authors reported that
P108A decreased oxytocin binding but did not signiﬁcantly
aﬀect Gq activation as measured by inositol phosphate
production, which was consistent with our results. Furthermore, our ﬁndings show that P108A impaired OXTR
desensitization, meaning that some OXTR Gq activation
occurred unopposed. This could result in premature initiation
of uterine contractions and thus explain an association between
P108A and premature labor. Future studies are needed to
determine whether P108Aand V45L, which we found to have
similarly impaired desensitization and structural changes
predispose patients to preterm labor.
Understanding how genetic variants alter receptor function is
an important step toward personalized drug dosing. Our
functional annotation of the 11 most prevalent variants of
unknown signiﬁcance in OXTR helped us to prioritize the
variants most likely to aﬀect OXTR function for further study.
These variants caused EC50 changes in the 2−4-fold range,
consistent with eﬀects caused by other naturally occurring
GPCR variants linked to disease risk and drug response.55−58
Additionally, our data indicate that the two most prevalent
missense variants, A218T and A238T, are unlikely to
appreciably aﬀect OXTR function.
Both activation and desensitization of the Ca2+ signaling
pathway play an important role in determining clinical response
to oxytocin. Currently, most oxytocin dosing protocols for labor
induction call for providers to increase the oxytocin infusion
rate at steady intervals, which compensates for a given amount
of OXTR desensitization over time.59 Imbalance between these
processes, also known as signaling bias, may therefore have
clinical consequences, as shown in other GPCRs.19,58,60 In our
study, we identiﬁed three variants that may cause signaling bias:
(1) V45L and P108A impaired OXTR desensitization but not
activation and (2) V281M decreased OXTR activation but not
desensitization. However, further studies are necessary to
determine whether these changes represent signaling bias
between β-arrestin and Gq. Our data indicate that individuals
who carry the V281M allele may be less responsive to oxytocin
but still susceptible to the potential adverse eﬀects that result
from OXTR desensitization during labor (i.e., postpartum
hemorrhage, uterine atony). These individuals may require
higher doses of oxytocin to achieve labor induction and thus
may have increased risk of these adverse events. Furthermore,
oxytocin may be less eﬀective in preventing postpartum
hemorrhage in these individuals. In contrast, patients with
V45L or P108A variants may be less susceptible to the adverse
eﬀects that result from OXTR desensitization but more
susceptible to uterine hyperstimulation as a result of induction

receptors per cell. Because Gq signaling ampliﬁes through the
signaling pathway that leads to Ca2+ mobilization, intracellular
Ca2+ is not a one-to-one readout of Gq activation.51 A more
direct measurement of Gq activation may show that maximal
Gq activation correlates with surface OXTRs, but this may not
translate directly to the activation of downstream pathways
important for myometrial contractions.
Unlike maximal Ca2+ signaling, maximal recruitment of βarrestin measured in the bioluminescence resonance energy
transfer screen closely matched the number of OXTRs on the
cell membrane. P108A and L206V, which increased cell surface
OXTR, caused higher maximal recruitment (Emax), whereas
V281M and E339K, which decreased cell surface OXTR,
caused lower maximal recruitment (Figure 1E, G). Changes in
Emax in our bioluminescence resonance energy transfer assays
seemed to reﬂect a change in the number of receptors available
to recruit β-arrestin but did not always correspond to functional
changes in receptor desensitization or internalization (Figure
4). For example, the L206V and V281M variants had the largest
eﬀects on Emax for β-arrestin recruitment but did not alter
receptor desensitization or internalization. In contrast, increases
in the EC50 for β-arrestin recruitment corresponded to right
shifts in desensitization and internalization curves. Whereas
OXTR desensitization and internalization can occur by several
mechanisms, our results suggest that changes in β-arrestin
recruitment EC50 translate to functional diﬀerences in
desensitization and internalization.
To complement our in vitro assays, we used an in silico
method to model the behavior of variant OXTRs. Our in vitro
assays showed that V45L and P108A caused rightward shifts in
the dose−response curves for β-arrestin recruitment, OXTR
desensitization, and OXTR internalization but not oxytocininduced Ca2+ signaling. We used the deep-learning approach
DiﬀNets to identify structural changes that were common to
V45L and P108A OXTRs but not present in OXTRs with
normal internalization and desensitization. Importantly, the
DiﬀNet required no input of information about OXTR/GPCR
structure/function relationships to identify locations in OXTR
that appear to be associated with β-arrestin binding. This
discovery-based approach yielded predictions that correspond
with our in vitro data as well as published work on the
mechanism of β-arrestin binding in other GPCRs.49 The
structural diﬀerences shown in Figure 6 suggest one mechanism
by which OXTR can bind to and activate G proteins without
activating β-arrestin. However, further work is necessary to
validate these predictions and determine the mechanism of βarrestin binding to OXTR. In the future, these ﬁndings may
guide the design of biased agonists, as recently demonstrated by
Suomuoviri et al. for the angiotensin II type 1 receptor.52 Novel
uterotonics that mimic the eﬀects of V45L and P108A may
preferentially activate OXTR signaling through Gq with less βarrestin activation, thus decreasing the risk of adverse eﬀects
associated with OXTR internalization and desensitization.
We used a similar approach to identify conformational
changes associated with V281M, a variant that decreased
OXTR activation (oxytocin-induced Ca2+ signaling) but had no
eﬀect on desensitization or internalization. Our Markov State
Models predicted conformational changes in V281M OXTR
consistent with steric hindrance of G protein binding (Figure
7). Importantly, these changes would not hinder binding of βarrestin and thus present a possible mechanism by which
V281M altered Ca2+ signaling without altering desensitization
or internalization. However, the changes caused by V281M
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with oxytocin. Finally, patients with the E339K variant, which
impairs OXTR activation and desensitization to roughly the
same extent, may require higher oxytocin doses to achieve
clinical eﬀects.
Our studies indicate that individuals who carry the V45L,
P108A, V281M, or E339K variants may beneﬁt from
personalized oxytocin dosing protocols or alternative methods
of labor induction. P108A is found in 0.3% of the Finnish
population, V281M is found in 0.7% of the Swedish population,
and E339K is found in 1.5% of the Ashkenazi Jewish
population.18,61 Further studies in these populations are
necessary to determine the utility of genetic analyses in
developing precision medicine approaches to oxytocin dosing.
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